摘要 |
Compounds having the formula <IMAGE> or a pharmaceutically acceptable salt thereof wherein Y is selected from halogen, alkyl, and haloalkyl; n is 0, 1, 2, or 3; X is absent or is alkylene; A is absent or is selected from optionally substituted alkylene, optionally substituted cycloalkylene, optionally substituted cycloalkylene wherein one or two of the carbon atoms is replaced with one or two heteroatoms independently selected from O, S, and N, optionally substituted alkenylene, and <IMAGE> or R2 and A together define a saturated 5- to 8-membered optionally substituted carbocyclic or heterocyclic ring to which the group Z is attached; Z is selected from (a) hydrogen, (b) COM wherein M is selected from the group consisting of -OR5, a pharmaceutically acceptable cation, -NR7R8, and a pharmaceutically acceptable, metabolically cleavable group, (c) -OR3, (d) tetrazolyl, (e) -CH(OR3)-CH2OR9, (f) -CH(OR3)-CH2-CH2OR9, (g) -CH(OR3)-CH(OR9)-CH2OR10, and (h) =N-OR3; and R1, R2, R3, R9, and R10 are independently selected from (a) hydrogen, (b) alkyl, and (c) optionally substituted phenyl, are prostaglandin biosynthesis inhibitors and are useful in the treatment of inflammatory disease states. Also disclosed are prostaglandin inhibiting compositions, a method of inhibiting prostaglandin biosynthesis in a mammal. |